Drug Delivery

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of inducing antigen-specific regulatory T cells (Tregs), the immune cells that play a central role in suppressing excessive immune responses. The findings, now published in Drug Delivery, may pave the way for next-generation therapies for autoimmune and allergic diseases, where unwanted immune activation must be precisely controlled.